OHDSI APAC Community Call

20251218

Agenda

- OHDSI News
- 2025 OHDSI APAC Symposium Recap
- APAC 2025 Closing: *How did OHDSI APAC do in 2025*

OHDSI India Symposium Dec. 2

2026 OHDSI Europe Symposium

Deadline for abstract submission is **Feb. 6, 2026**

Registration has not opened yet

2026 OHDSI Global Symposium

2026 OHDSI Global Symposium

Oct. 20-22 • New Brunswick, N.J. • Hyatt Regency Hotel

The 12th annual OHDSI Global Symposium will return to the Hyatt Regency Hotel in New Brunswick, N.J., Oct. 20-22, 2026. All pertinent information will be added to this page when available. Currently, the OHDSI steering group is seeking proposals for both plenaries and tutorials. **The deadline for both is January 30, 2026; more details are below.**

2025 OHDSI APAC Symposium

December 6-7 • Shanghai Jiao Tong University, China

OHDSI
WELCOMES YOU TO
OHDSI
APAC Symposium 2025
December 6-7, 2025
Hosted by Shanghai Jiao Tong University, China

OHDSI APAC Symposium: Tutorial day



From Global to Regional Impact – OHDSI Across APAC

From Research to Reflection:

APAC Studies and Lessons Learned

Database, from FPG to medical burden
Changran Wang from Fudan Univ.

Gastrointestinal Risk of GLP-1 RA vs. SGLT-2i in T2DM: A Distributed Network Observational Study – Overview, Progress and Experimental Insights
Sun Feng from Peking Univ.

Study the Disease Trajectory of T2DM with Transformer-based Model: Lessons Learned
Sihui Luo from USTC

Lightning Talks

From Regional Insights to Local Challenges:

Real-world Evidence and OHDSI/OMOP in China

Take your research out into the world!

My insights

Networking

Face-to-Face

Momentum

2025 OHDSI APAC Symposium Reflection (by Hanjae Kim)

18 Dec 2025



Hanjae Kim

(Mar 2025 - Present) Department of Biomedical Systems Informatics, Yonsei University College of Medicine – Master's program

(Mar 2017 - Feb 2024) Yonsei University College of Nursing – B.S.

Email: oneash082498@yuhs.ac / oneash082498@gmail.com

LinkedIn: www.linkedin.com/in/hanjae-kim

Instagram: @oneash0824

First year in graduate school.

First time in OHDSI Symposium.

Dec 6-7, 2025 (Shanghai)

Day 1: Tutorial Session

Day 1 (December 6) – Full Tutorial at Room 102, Dongxia Yuan Building (Zheng-Cai Cu

Time	Agenda/Speaker
08:30 - 09:00	Reception
09:00 - 09:20	OHDSI/OMOP Introduction Mui Van Zandt
09:20 - 10:00	OMOP CDM and Vocabulary Mukkesh Kumar and Erwin Tantoso
10:00 - 10:30	OMOP Conversion Process Evelyn Goh
10:30 - 10:40	Break
10:40 - 12:00	ETL Exercises Gyeol Song
12:00 - 13:30	Lunch
13:30 - 14:50	OHDSI Analyses: Building Cohorts Seng Chan You
14:50 - 15:30	CohortDiagnostics and Population-Level Estimation Thanh-Phuc Phan
15:30 - 15:50	Break
15:50 - 16:30	Interpreting Results Nicole Pratt

Dinner with Yongqi, Xiaowei from Peking Univ.

Day 2: Main Conference



Day 2: Main Conference

Day 2: Main Conference

Thank You!

OHDSI
WELCOMES YOU TO
OHDSI
APAC Symposium 2025
December 6-7, 2025
Hosted by Shanghai Jiao Tong University, China

From Online to In-Person: My First Year with OHDSI APAC

Yongqi Zheng, Department of Epidemiology and Biostatistics, Peking University

My journey into OHDSI APAC (2025)

- Guided by Prof. Sun, I joined the APAC China study collaboration
- Started my own OHDSI-based research: Gastrointestinal Risk of GLP-1 Receptor Agonists versus SGLT-2 Inhibitors in Type 2 Diabetes: A Distributed Network Observational Study

Analytic use case	Type	Structure
Population-level effect estimation	**Comparative effectiveness**	Does exposure to **GLP-1RAs** have a different risk of experiencing **gastroparesis or intestinal obstruction** within **end of continuous observation**, relative to **DPP4-i or SGLT2is** among the population with **type 2 diabetes and history of metformin**?

- **Learning → Contributing**

Learning through regular engagement

- Bi-weekly APAC Study meetings: discussions, progress updates, peer support
- Learning ATLAS and the OHDSI workflow hands-on
- Joining the monthly OHDSI APAC Community Call
- Meeting many members via online channels



Sorry— I forgot to take a screenshot of the meeting :(

APAC Symposium in Shanghai

- Day 1: Tutorials (hands-on learning)
- Day 2: Symposium (community, networks, collaboration)
- My takeaway: OHDSI feels collaborative, fast-moving, inclusive, and welcoming to newcomers
- Personal note: I expected the tutorials to feel “new,” but they felt surprisingly familiar
  - Online meetings helped me learn the workflow in advance, so the in-person sessions felt warm, smooth, and instantly connected



From online to in-person: finally meeting the community

- Great to meet people I previously only knew
- Many members I didn't get a chance to take photos with—but I'm grateful to have met you

Other moments

- A fun activity: signing a globe balloon and passing it to others
- Why it is most memorable: it made the global participation feel tangible—people from different places, working on together

Informal conversations at tea breaks and dinners

Looking ahead: how I could contribute

- Continue pushing my research forward within OHDSI standards
- Share practical OHDSI tools and workflows (ATLAS/HADES, diagnostics, reproducible pipelines)
- Collaborate with partners who need support—share methods, share evidence, and co-build reliable results

My first year with OHDSI (2025)

Xiaowei Chen

Department of Epidemiology and Biostatistics, School of Public Health, Peking University

My OHDSI journey in 2025

March

Study proposal session

- OHDSI China Collaborators
- Pre: The effect of angiotensin-receptor blocker (ARB) on the development of chronic diabetic complications in patients with type 2 diabetes mellitus: a target trial emulation study (not be selected)

Apr–Nov

Bi-weekly Meeting

- Lurking and learning in PKU 2025 APAC China Study 2 (regular calls, methods & OMOP)

Dec

APAC Symposium (Shanghai)

- Poster + lightning talk
- Pre: Effectiveness and safety of sitagliptin added to metformin in real - world type 2 diabetes patients: a target trial emulation study

Theme: learning through open collaboration

March: Study proposal session

What I presented

The effect of angiotensin-receptor blocker (ARB) on chronic diabetic complications in T2DM: a target trial emulation study

- Protocol-first thinking: Sequential trial TTE, define interventions, outcomes, assignment procedures, time zero and follow-up schedules, causal contrasts and statistical analysis methods clearly
- Outcome phenotyping & validation are as important as modeling
- Plan sensitivity analyses early (lag periods, PP analysis, etc.)

Expert feedback I received

- Well-designed study, but a sequential trial framework is not yet established in the OHDSI network
- Define clear active comparator to strengthen visibility and provide more reliable evidence
- Sequential trials are challenging without a clear indication for ARBs—consider restricting to routine clinical indications (e.g., hypertension)
- A quick update—based on the feedback, refined the design and completed the study in the Yinzhou database. It was accepted for a spotlight poster presentation at ACPE in Hong Kong, and was presented in November

Although not selected as a 2025 APAC Study, the discussion was hugely valuable.

Apr–Nov: Learning in APAC China Study 2-PKU

What I did

- Attended 2025 APAC China Study 2 (PKU Yongqi) calls every 2 weeks
- Listened to study design, implementation, and troubleshooting discussions
- Followed how a multi-site OHDSI study progresses from idea → protocol → analysis → pooled results

What I learned

- OMOP CDM mindset: standardized data enables scalable, federated evidence
- Cohort definitions in ATLAS: iterating inclusion/exclusion is a key skill
- Diagnostics should be routine
- Feasibility analysis
- Collaboration workflow: transparent documentation + version control (e.g., GitHub)

This “shadowing” experience made the community feel approachable and learnable.

Dec: 2025 OHDSI APAC Symposium (Shanghai)

My contribution

Selected for BOTH:

Poster | **Lightning talk**

Effectiveness and safety of sitagliptin added to metformin in real-world T2DM patients: a target trial emulation study

What I gained

- In-person meets and discussions with collaborators I previously only met online
- Hands-on OMOP courses: mapping, cohort building, and study execution
- New ideas from other studies (phenotyping, transportability, and diagnostics)
- Confidence from presenting and receiving constructive questions



Reflections & insights from the Symposium

1) Community matters

- Friendly and supportive culture lowers the barrier for newcomers
- Open sharing (protocols, code, diagnostics) accelerates collective learning

2) OMOP is the foundation

- Mapping and data quality checks determine what questions are answerable
- Cohort definitions are “living objects” that need iteration and review

3) RWS needs transparency

- Be explicit about index date, confounding control, censoring rules, diagnostics and cohort definitions
- Should be reported as first-class results

4) Academic networking is powerful

- Regular communication often unlocks collaboration opportunities
- It helps align expectations and build trust for multi-site studies

What I hope to work on next

My research focus

- Real-world studies of effectiveness & safety evaluation of drugs in chronic diseases, especially type 2 diabetes, COPD, and hypertension
- Target Trial Emulation + robust causal inference in OMOP CDM data

How I want to contribute in OHDSI

- Join more APAC studies and collaborate across sites
- Share my protocols and ideas
- Contribute to phenotyping, diagnostics, and methods discussions
- Connect with partners who are interested in similar chronic-disease drug questions

Thank you

Xiaowei Chen
Peking University
chen_xiaowei@hsc.pku.edu.cn; chenxiaowei1108@163.com

APAC 2025 Closing

OHDSI's mission

To improve health by empowering a community to collaboratively generate the evidence that promotes better health decision and better care

2025 OHDSI APAC Goals

Research

Guideline-driven Evidence Generation

Evidence-driven Data standardization

Build research expertise and collaboration amongst the different chapters through publication

Milestones

- Continue and complete 2024 APAC Study (GLP-1 ALI)
- Select and conduct 2-3 new network studies led by APAC
- Strengthen APAC presence in OHDSI Evidence Network

Training

Evidence-driven Data standardization

Evidence-driven Collaborative Education

Create an APAC training program to expand reach to the general community and provide more opportunities for hands-on learning

Milestones

- Formalize an OHDSI/OMOP curriculum in APAC
- Conduct a community-wide project on ETL and/or vocabulary mapping
- Support update and localization of Book of OHDSI

Communication

Guideline-driven Evidence Generation

Create collaboration activities that encourage collaborative generation and dissemination of evidence that promotes better health decisions and better care

Milestones

- Host APAC symposium and issue certificates for participation
- Distribute quarterly newsletters
- Host monthly community calls and scientific forums

2025 APAC Highlights & Achievements

- **Advancing Science: OHDSI-related publications across APAC**

- Janetzki, J.L.; Kim, J.H.; Minty, E.; Lee, J.A.; Morales, D.R.; Khera, R.; Kim, C.; Alshammari, T.M.; DuVall, S.L.; Matheny, M.E.; Falconer, T.; Kim, S.; Phan, T.P.; Nguyen, P.A.; Hsu, M.H.; Hsu, J.C.; Park, R.W.; Man, K.K.C.; Seager, S.; Zandt, M.V.; Gilbert, J.P.; Ryan, P.B.; Schuemie, M.J.; Suchard, M.A.; Hripcsak, G.; Pratt, N.; You, S.C.* (2025/03) "Risk of aortic aneurysm or dissection following use of fluoroquinolones: a retrospective multinational network cohort study", eClinicalMedicine, 81:103096.
- Yu Y, Zheng Y, Zhang M, Xie J, You S, Feng M, Zhan S, Sun F. Attitudes Toward Common Data Models Among Chinese Biomedical Professionals: Cross-Sectional Survey. JMIR Medical Informatics 2025;13:e77603
- Woo Yeon Park, Teri Sippel Schmidt, Gabriel Salvador, Kevin O'Donnell, Brad Genereaux, Kyulee Jeon, Seng Chan You, Blake E Dewey, Paul Nagy, Alzheimer's Disease Neuroimaging Initiative , Breaking data silos: incorporating the DICOM imaging standard into the OMOP CDM to enable multimodal research, *Journal of the American Medical Informatics Association*, Volume 32, Issue 10, October 2025, Pages 1533–1541, https://doi.org/10.1093/jamia/ocaf091
- Jeon, K., Park, W. Y., Kahn Jr, C. E., Nagy, P., You, S. C., & Yoon, S. H. (2025). Advancing medical imaging research through standardization: The path to rapid development, rigorous validation, and robust reproducibility. *Investigative radiology*, *60*(1), 1-10.
- Yu, Y., Zheng, Y., Zhang, M., Xie, J., You, S. C., Feng, M., ... & Sun, F. (2025). Attitudes Toward Common Data Models Among Chinese Biomedical Professionals: Cross-Sectional Survey. *JMIR Medical Informatics*, *13*, e77603.
- Park, C., Lee, S. H., Lee, D. Y., Choi, S., You, S. C., Jeon, J. Y., ... & Park, R. W. (2025). Analysis of Retinal Thickness in Patients With Chronic Diseases Using Standardized Optical Coherence Tomography Data: Database Study Based on the Radiology Common Data Model. *JMIR Medical Informatics*, *13*, e64422.
- Feng, L., Wang, W., Yin, C., Li, J., Zhang, X., Chang, X., ... & Wang, G. (2025). Risk of Switch to Mania/Hypomania in Bipolar Depressive Patients Treated with Antidepressants: A Real-World Study. *Health Data Science*, *5*, 0209.
- Kim, S. M., Choi, S., Lee, Y. K., Lim, C. W., Yu, B. C., Park, M. Y., ... & Choi, S. J. (2025). Exploring the Possibility of Medical Device Surveillance in Patients on Peritoneal Dialysis Using a Common Data Model. *Medicina*, *61*(5), 814.
- Haber, R., Webster-Clark, M., Pratt, N., Barclay, N., Li, X., Maro, J. C., ... & Filion, K. B. (2025). Core Concepts in Pharmacoepidemiology: Multi-Database Distributed Data Networks. *Pharmacoepidemiology and Drug Safety*, *34*(7), e70177.
- Kalisch Ellett, L. M., Janetzki, J. L., Lim, R., Laba, T. L., & Pratt, N. L. (2025). Innovations in pharmacovigilance studies of medicines in older people. *British journal of clinical pharmacology*, *91*(1), 66-83.
- Norén, G. N., Donegan, K., Muñoz, M. A., Alshammari, T. M., Pratt, N., Candore, G., ... & Ryan, P. B. (2025). Recommendations to Enable Broader Use of Real-World Evidence to Inform Decision-Making Throughout Pharmacovigilance Signal Management. *Pharmacoepidemiology and Drug Safety*, *34*(10), e70231.
- **……**

2025 APAC Highlights & Achievements

- **Expanding Research Capacity**
  - Three OHDSI-Framework Studies
    - **Peking University** *"Gastrointestinal Risk of GLP-1 Receptor Agonist versus SGLT-2 inhibitors in T2DM"*
    - **Fudan University** *"Association Between Fasting Plasma Glucose Levels and Annual Hospitalization Days: A Multicenter Study Using the OHDSI Framework"*
    - **USTC** *"Studying the Disease Trajectory of T2DM with Transformer-based model"*

2025 APAC Highlights & Achievements

- **Strengthening the Community**
  - Monthly Community Calls and Scientific Forums

All videos are archived here!
Subscribe to stay up to date with the latest updates.

  - Quarterly Newsletters
  - 2025 OHDSI APAC Symposium

Next in 2026

OHDSI APAC Symposium

2026 in Korea

Thank you all for your hard work throughout 2025,
and Merry Christmas!